KR20180106974A - 항-tnf 알파 항체의 액상 제제 - Google Patents

항-tnf 알파 항체의 액상 제제 Download PDF

Info

Publication number
KR20180106974A
KR20180106974A KR1020180031016A KR20180031016A KR20180106974A KR 20180106974 A KR20180106974 A KR 20180106974A KR 1020180031016 A KR1020180031016 A KR 1020180031016A KR 20180031016 A KR20180031016 A KR 20180031016A KR 20180106974 A KR20180106974 A KR 20180106974A
Authority
KR
South Korea
Prior art keywords
formulation
liquid formulation
arginine
concentration
sucrose
Prior art date
Application number
KR1020180031016A
Other languages
English (en)
Korean (ko)
Inventor
윤소라
고연경
소진언
Original Assignee
주식회사 엘지화학
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63522490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20180106974(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 주식회사 엘지화학 filed Critical 주식회사 엘지화학
Publication of KR20180106974A publication Critical patent/KR20180106974A/ko
Priority to KR1020200098144A priority Critical patent/KR102342292B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020180031016A 2017-03-16 2018-03-16 항-tnf 알파 항체의 액상 제제 KR20180106974A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020200098144A KR102342292B1 (ko) 2017-03-16 2020-08-05 항-tnf 알파 항체의 액상 제제

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170033188 2017-03-16
KR20170033188 2017-03-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020200098144A Division KR102342292B1 (ko) 2017-03-16 2020-08-05 항-tnf 알파 항체의 액상 제제

Publications (1)

Publication Number Publication Date
KR20180106974A true KR20180106974A (ko) 2018-10-01

Family

ID=63522490

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020180031016A KR20180106974A (ko) 2017-03-16 2018-03-16 항-tnf 알파 항체의 액상 제제
KR1020200098144A KR102342292B1 (ko) 2017-03-16 2020-08-05 항-tnf 알파 항체의 액상 제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020200098144A KR102342292B1 (ko) 2017-03-16 2020-08-05 항-tnf 알파 항체의 액상 제제

Country Status (15)

Country Link
JP (2) JP7109849B2 (es)
KR (2) KR20180106974A (es)
CN (1) CN110621303A (es)
AU (1) AU2018236651B2 (es)
BR (1) BR112019019162A2 (es)
CO (1) CO2019010860A2 (es)
MA (1) MA46988A1 (es)
MX (1) MX2019010895A (es)
MY (1) MY197202A (es)
NZ (1) NZ757965A (es)
PH (1) PH12019502075A1 (es)
RU (1) RU2756619C2 (es)
UA (1) UA123847C2 (es)
WO (1) WO2018169348A1 (es)
ZA (1) ZA201906696B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3129901A1 (en) * 2019-02-18 2020-08-27 Eli Lilly And Company Therapeutic antibody formulation
TW202102260A (zh) * 2019-03-21 2021-01-16 美商再生元醫藥公司 含有抗ｉｌ－３３抗體之穩定調配物
WO2021164717A1 (zh) * 2020-02-20 2021-08-26 百奥泰生物制药股份有限公司 抗TNF-α的抗体制剂及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2637690T3 (pl) * 2010-11-11 2017-03-31 Abbvie Biotechnology Ltd Płynne formulacje zawierające przeciwciało anty-tnf alfa o wysokim stężeniu
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
WO2013164837A1 (en) * 2012-03-07 2013-11-07 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies
KR102362829B1 (ko) 2012-09-07 2022-02-15 코히러스 바이오사이언시즈, 인코포레이티드 아달리무맙의 안정한 수성 제형
JP2016505633A (ja) 2013-01-24 2016-02-25 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ ＴＮＦα抗原結合性タンパク質
AR095496A1 (es) 2013-03-15 2015-10-21 Bayer Healthcare Llc Formulaciones de anticuerpos anti-receptor de prolactina
US20150274819A1 (en) 2014-03-03 2015-10-01 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
WO2015151115A1 (en) * 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of adalimumab
ES2600488T3 (es) * 2014-05-23 2017-02-09 Ares Trading S.A. Composición farmacéutica líquida
US9821059B2 (en) 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
WO2016120413A1 (en) * 2015-01-28 2016-08-04 Mabxience S.A. Pharmaceutical formulations for anti-tnf-alpha antibodies
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody

Also Published As

Publication number Publication date
JP7109849B2 (ja) 2022-08-01
JP2022097600A (ja) 2022-06-30
WO2018169348A1 (ko) 2018-09-20
BR112019019162A2 (pt) 2020-04-14
AU2018236651B2 (en) 2020-12-10
MY197202A (en) 2023-05-31
PH12019502075A1 (en) 2020-09-14
RU2019130728A (ru) 2021-04-16
RU2019130728A3 (es) 2021-04-16
CN110621303A (zh) 2019-12-27
KR20200096472A (ko) 2020-08-12
NZ757965A (en) 2022-07-01
UA123847C2 (uk) 2021-06-09
CO2019010860A2 (es) 2020-01-17
MX2019010895A (es) 2019-11-05
JP2020510079A (ja) 2020-04-02
MA46988A1 (fr) 2020-06-30
AU2018236651A1 (en) 2019-10-31
ZA201906696B (en) 2020-08-26
RU2756619C2 (ru) 2021-10-04
KR102342292B1 (ko) 2021-12-24

Similar Documents

Publication Publication Date Title
US11179463B2 (en) BLyS antibody formulation
US20190345238A1 (en) Formulations
TWI353253B (es)
KR102342292B1 (ko) 항-tnf 알파 항체의 액상 제제
AU2016217806A1 (en) Stable liquid formulation for monoclonal antibodies
EP2081553B1 (en) Stable antibody formulations
EP3532029B1 (en) Liquid pharmaceutical composition
JP7465814B2 (ja) 高濃度タンパク質製剤の粘度低下
BR112016025126B1 (pt) Composição aquosa compreendendo anticorpo neutralizante de gmcsf, e uso da mesma
JP2017105754A (ja) 低粘度抗体組成物
WO2008029908A1 (fr) Préparation pharmaceutique lyophilisée stable comprenant un anticorps
AU2014201388B2 (en) Stable Buffered Formulations Containing Polypeptides
KR20240053633A (ko) Vegf 수용체 융합 단백질을 위한 제제
EP3533441A2 (en) Stable pharmaceutical formulation

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
X601 Decision of rejection after re-examination
A107 Divisional application of patent